Health Technology
SAMSUNG BIOLOGICS Co., Ltd.
In the news
- Samsung Biologics to invest $1.5bn for new pharmaceutical plant Aug 11, 2020
- Samsung Biologics snags $1.5bn in orders on pandemic rush Jun 29, 2020
- Toyota AGM, Macao casino regulator, Vietnam-EU trade deal Jun 7, 2020
- South Korea seeks arrest of Samsung heir in succession probe Jun 4, 2020
- Kakao tops Hyundai in market cap as pandemic shakes up Korea Inc. May 25, 2020 See more articles on SAMSUNG BIOLOGICS Co., Ltd.
Business Summary
SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.
Financial Highlights
| Dec 2020 | KRW | USD |
| Revenue | 1,164.77B | 987.19M |
| Gross Profit | 469,262.42M | 397.71M |
| Operating income | 293,299.68M | 248.58M |
| Income before tax | 283,759.85M | 240.49M |
| Net income | 240,974.79M | 204.23M |
| EBITDA | 436,474.55M | 369.92M |
| Diluted EPS | 3,642.02 | 3.08 |
| Dividends Per Share | 0 | 0 |
| Total Assets | 6,424.20B | 5,913.83M |
| Total liabilities | 1,825.41B | 1,680.39M |
| Total equity | 4,598.78B | 4,233.43M |
| Operating cash flow | 202,090.02M | 171.27M |
| Currency in KRW | Currency in USD |
Historical Data
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | |
| Revenue | 294,622.02M | 464,629.33M | 535,805.80M | 701,591.85M | 1,164.77B |
| Gross Profit | 20,457.76M | 122,304.94M | 130,544.55M | 230,536.76M | 469,262.42M |
| Operating income | -30,422.63M | 65,979.40M | 55,678.74M | 92,084.47M | 293,299.68M |
| Income before tax | -101,678.33M | -115,994.75M | 302,975.83M | 82,495.19M | 283,759.85M |
| Net income | -176,823.40M | -96,972.11M | 224,109.19M | 202,904.09M | 240,974.79M |
| EBITDA | 29,727.25M | 135,905.62M | 147,129.29M | 224,627.48M | 436,474.55M |
| Diluted EPS | -3,115 | -1,466 | 3,387 | 3,066.63 | 3,642.02 |
| Dividends Per Share | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 7,533.01B | 7,183.09B | 5,980.40B | 5,911.62B | 6,424.20B |
| Total liabilities | 3,450.63B | 3,206.64B | 1,824.94B | 1,557.17B | 1,825.41B |
| Total equity | 4,082.37B | 3,976.45B | 4,155.46B | 4,354.45B | 4,598.78B |
| Operating cash flow | -62,661.29M | 149,816.32M | 36,787.30M | 10,153.61M | 202,090.02M |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | |
| Revenue | 253.94M | 410.99M | 486.86M | 601.61M | 987.19M |
| Gross Profit | 17.63M | 108.18M | 118.62M | 197.68M | 397.71M |
| Operating income | -26.22M | 58.36M | 50.59M | 78.96M | 248.58M |
| Income before tax | -87.63M | -102.60M | 275.30M | 70.73M | 240.49M |
| Net income | -152.40M | -85.77M | 203.63M | 173.98M | 204.23M |
| EBITDA | 25.62M | 120.21M | 133.69M | 192.61M | 369.92M |
| Diluted EPS | -2.68 | -1.29 | 3.07 | 2.62 | 3.08 |
| Dividends Per Share | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 6,236.97M | 6,709.72M | 5,359.74M | 5,111.87M | 5,913.83M |
| Total liabilities | 2,856.96M | 2,995.32M | 1,635.54M | 1,346.51M | 1,680.39M |
| Total equity | 3,380.01M | 3,714.39M | 3,724.20M | 3,765.36M | 4,233.43M |
| Operating cash flow | -54.00M | 132.52M | 33.42M | 8.70M | 171.27M |
Valuation Measures
| Dec 2020 | |
| PER | 226.79 |
| ROA | 3.90% |
| ROE | 5.38% |
| Operating margin | 25.18% |
| Profit margin | 20.68% |
Key executives
- President, Chief Executive Officer & Director: John Chongbo Rim
- Chief Financial Officer, Director & Senior VP: Dong-Joong Kim
- Managing Director & Head-Information Technology: James J. Choi
- Managing Director & Head-Process Technology: Yong-Ho An
- Head-Compliance Support: Hyung-Woo Moon
Shareholders
- Samsung C&T Corp. (43.4%)
- Samsung Electronics Co., Ltd. (31.4%)
- Invesco Advisers, Inc. (1.7%)
- Canada Pension Plan Investment Board (0.6%)
- BlackRock Fund Advisors (0.5%)
- Samsung Asset Management Co., Ltd. (0.5%)
- The Vanguard Group, Inc. (0.4%)
- Norges Bank Investment Management (0.3%)
- Fidelity Management & Research Co. LLC (0.2%)
- BlackRock Advisors (UK) Ltd. (0.2%)
Contact Details
- Website:http://www.samsungbiologics.com
- Address: 300 Songdo Bio Way, Yeonsu-gu, Inchon, 21987, South Korea
- Phone: +82.32.455.3114
Related Companies
- PengTai Greater China Co., Ltd.
- Samsung BioLogics Co., Ltd. ESOA
- Samsung Romania
Competitors
- Lonza Group AG
- Wuxi Biologics (Cayman) Inc.
- PanGen Biotech, Inc.
- Celltrion, Inc.
- Binex Co., Ltd
- AbClon, Inc.
- Bukwang Pharmaceutical Co., Ltd.
- Celltrion Healthcare Co., Ltd.
- Coherus BioSciences, Inc.
- EPIRUS Biopharmaceuticals, Inc.
- Kodiak Sciences, Inc.
- PharmAbcine Inc.
- PharmGen Science, Inc.
- Reyon Pharmaceutical Co., Ltd.
- SK Chemicals Co., Ltd.
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 6 May, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.